| Dr Anees Ahmed, MD | |
|
357 E Center St, #2, Manchester, CT 06040-4472 | |
| (860) 649-1178 | |
| Not Available |
| Full Name | Dr Anees Ahmed |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 54 Years |
| Location | 357 E Center St, Manchester, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184692089 | NPI | - | NPPES |
| 001332642 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 033264 (Connecticut) | Primary |
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487689022 PECOS PAC ID: 8022915677 Enrollment ID: O20040319000169 |
News Archive
When COVID-19 patients began filling up ICUs throughout the country in 2020, health care providers faced difficult decisions. Health care workers had to decide which patients were most likely to recover with care and which were not so resources could be prioritized.
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment, the researchers say, may lead to more successful outcomes for children with this often-deadly cancer.
USA Today: Entitlements Or Investment? Democrats Must Pick
NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chemoattractant Protein-1 (MCP-1) targeting anti-inflammatory Spiegelmer®, NOX-E36. NOXXON plans to develop NOX-E36 for the treatment of diabetic nephropathy and other diabetes related complications.
deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.
› Verified 5 days ago
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245256247 PECOS PAC ID: 8022915677 Enrollment ID: O20040319000535 |
News Archive
When COVID-19 patients began filling up ICUs throughout the country in 2020, health care providers faced difficult decisions. Health care workers had to decide which patients were most likely to recover with care and which were not so resources could be prioritized.
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment, the researchers say, may lead to more successful outcomes for children with this often-deadly cancer.
USA Today: Entitlements Or Investment? Democrats Must Pick
NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chemoattractant Protein-1 (MCP-1) targeting anti-inflammatory Spiegelmer®, NOX-E36. NOXXON plans to develop NOX-E36 for the treatment of diabetic nephropathy and other diabetes related complications.
deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.
› Verified 5 days ago
| Entity Name | Community Renewal Team Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841301876 PECOS PAC ID: 7618956939 Enrollment ID: O20040827000903 |
News Archive
When COVID-19 patients began filling up ICUs throughout the country in 2020, health care providers faced difficult decisions. Health care workers had to decide which patients were most likely to recover with care and which were not so resources could be prioritized.
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment, the researchers say, may lead to more successful outcomes for children with this often-deadly cancer.
USA Today: Entitlements Or Investment? Democrats Must Pick
NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chemoattractant Protein-1 (MCP-1) targeting anti-inflammatory Spiegelmer®, NOX-E36. NOXXON plans to develop NOX-E36 for the treatment of diabetic nephropathy and other diabetes related complications.
deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anees Ahmed, MD 21 Banks Rd, Simsbury, CT 06070-2324 Ph: (860) 651-9970 | Dr Anees Ahmed, MD 357 E Center St, #2, Manchester, CT 06040-4472 Ph: (860) 649-1178 |
News Archive
When COVID-19 patients began filling up ICUs throughout the country in 2020, health care providers faced difficult decisions. Health care workers had to decide which patients were most likely to recover with care and which were not so resources could be prioritized.
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations. Removing some of the guesswork in diagnosis and treatment, the researchers say, may lead to more successful outcomes for children with this often-deadly cancer.
USA Today: Entitlements Or Investment? Democrats Must Pick
NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chemoattractant Protein-1 (MCP-1) targeting anti-inflammatory Spiegelmer®, NOX-E36. NOXXON plans to develop NOX-E36 for the treatment of diabetic nephropathy and other diabetes related complications.
deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.
› Verified 5 days ago
Dr. Allana R Lee, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-646-1222 | |
Michael John Dewberry, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 Center St, Manchester, CT 06040 Phone: 860-646-3888 Fax: 860-645-4132 | |
Manpreet Kaur, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-647-6827 Fax: 860-533-3452 | |
Dr. Constantine Zariphes, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 150 N Main St, Manchester, CT 06042 Phone: 860-533-3434 Fax: 860-647-6829 | |
Jonathan L Chasen, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 Center St, Manchester, CT 06040 Phone: 860-646-3888 Fax: 860-645-4132 | |
Dr. Joseph E. Podolski, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Department Of Psychiatry, Manchester, CT 06040 Phone: 860-647-6831 |